About Molecular Devices

Investor Information

Molecular Devices is now part of MDS Analytical Technologies, a division of MDS, Inc. Please see our Investor Relations pages for complete corporate information.

Background

Molecular Devices supplies high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Its systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics and combinatorial chemistry by facilitating the high-throughput and cost-effective identification and evaluation of drug candidates. Molecular Devices' product solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology, electrophysiology, and chemistry. Molecular Devices enables its customers to improve their research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. Molecular Devices has a record of developing innovative, first-to-market products that include instrumentation, software and reagent systems. Molecular Devices is based in Sunnyvale, California, and has offices in Union City, California, Downingtown, Pennsylvania, England, Germany, Korea, China and Japan.

History

Founded in 1983, Molecular Devices introduced its first microplate reader in 1987 and since then has continually broadened its solution set through a combination of internal R&D and acquisition. Molecular Devices acquired Universal Imaging Corporation in 2002 and Axon Instruments in 2004 broadening its portfolio to include electrophysiology products, scanners and analysis software for microarrays, and workstations for cell-based screening using high-resolution imaging. In March 2007, Molecular Devices was acquired by MDS, Inc. (Toronto, Canada). Molecular Devices and MDS division, MDS Sciex, have merged to become MDS Analytical Technologies.